Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and the Safety of Trafermin in Patients With Marginal Periodontitis in Japan

NCT00199290 is registered in ClinicalTrials.gov with Kaken Pharmaceutical as lead sponsor.

NCT NCT00199290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00199290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and the Safety of Trafermin in Patients With Marginal Periodontitis in Japan
Lead sponsor
Kaken Pharmaceutical
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2005
Completion date
December 31, 2007
Enrollment
267 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

periodontitis